About GenomOncology
GenomOncology is a precision oncology platform that transforms complex and fragmented oncology data into actionable intelligence for clinical decision support. The company addresses the unprecedented challenge facing oncology professionals navigating over 1,400 FDA indications and 15,000+ active clinical trials. GenomOncology's platform merges all assay and lab data into unified reports, delivers transparent and explainable AI that generates real-time, auto-generated data interpretations at the point of care, and automates clinical trial matching to customize patient treatment. The platform integrates seamlessly with laboratory information systems (LIS), laboratory information management systems (LIMS), and electronic health records (EHR) for automated, bidirectional data exchange. GenomOncology serves multiple stakeholders in the oncology ecosystem including molecular pathologists, lab technicians, clinical oncologists, clinical trial professionals, bioinformaticians, and clinical researchers. The company's solutions span three core areas: Molecular Pathology Solutions that accelerate reporting and eliminate bottlenecks, Clinical Trial Optimization that ensures patients never miss trial opportunities through real-time matching, and Data Enablement that unlocks the power of oncology data through automated extraction and normalization.
Clinical Focus
Medical conditions and clinical areas addressed by GenomOncology.
Who It Serves
Milestones & Awards
Recent Milestones
Strategic partnership with WeTrials announced to accelerate clinical trial enrollment for CNS cancer patients; EHR integration case study demonstrating automation from order to results
Key Partnerships
Company Details
- Headquarters
- Cleveland, OH, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.